# Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients

> **NCT01897714** · PHASE1,PHASE2 · TERMINATED · sponsor: **Oncopeptides AB** · enrollment: 75 (actual)

## Conditions studied

- Relapsed and/or Relapsed-refractory Multiple Myeloma

## Interventions

- **DRUG:** Melflufen
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01897714
- **Lead sponsor:** Oncopeptides AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2017-12
- **Final completion:** 2020-03
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** The study was terminated at median 46-48 months long term follow-up and mature overall survival follow-up data.
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01897714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01897714, "Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01897714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*